Artificial Intelligence (AI) in Life Sciences Market Size, Share & Trends Analysis Report By Technology (Machine Learning, Deep Learning, Natural Language Processing, Others), By Application (Drug Discovery, Medical Diagnosis, Biotechnology, Clinical Trials, Precision & Personalized Medicine, Others), By Drug Type (Small Molecule, Large Molecule), By Offering (Software, Services), By Indication (Immuno-Oncology, Neurodegenerative Diseases, Others), By End User (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Others), By Region (North America, Europe, APAC, Middle East and Africa, LATAM), Forecasts, 2026-2034

Artificial Intelligence (AI) in Life Sciences Market Size & Growth Analysis

The global artificial intelligence in life sciences market size was valued at USD 3.51 billion in 2025 and is projected to grow from USD 4.40 billion in 2026 to USD 26.68 billion by 2034, registering a CAGR of 25.28% during the forecast period from 2026 to 2034. North America dominated the artificial intelligence in life sciences market with a market share of 42.5% in 2025.

The adoption of AI in life sciences is accelerating, enhancing research, drug discovery, and data management across the product lifecycle. Increasing focus on precision medicine and personalized treatment is driving AI integration to improve diagnostics, treatment outcomes, and healthcare efficiency.

Application Insights

Based on application, the market is segmented into drug discovery, biotechnology, clinical trials, medical diagnosis, precision and personalized medicine, and patient monitoring. The drug discovery segment holds a significant market share and is estimated to grow at a CAGR of 30.2% during the forecast period. Drug discovery is the most significant life science application using artificial intelligence (AI) solutions. For instance, according to Taconic Biosciences' tally, an incredible amount of money and time goes into drug development and bringing a drug to market, costing about USD 2.8 billion over 12 years. AI solutions are increasingly becoming an essential component among several major pharmaceutical companies for creating a decision support system that analyzes various parameters and outcomes to help them decide to invest in particular drug discovery. Such a decision support system can help expedite the time taken to market the drug and give the end users an advantage in the highly competitive segment. Therefore, the factors mentioned above contribute to market growth.

One of the life sciences sector's most data-intensive responsibilities is conducting clinical studies. They collect enormous amounts of data daily while monitoring various patient characteristics. The researchers may find meaningful associations between loosely connected data by putting these data sets through intelligent AI systems. This motivates numerous pharmaceutical firms and clinical research institutions to invest in cutting-edge tools like artificial intelligence. The pharmaceutical business, which conducts more than 50% of all clinical trials annually worldwide, is closely monitoring the increasing uptake of AI in the current market context. Numerous well-known businesses, including GlaxoSmithKline, Sanofi, Pfizer Mitsubishi Tanabe Pharma, and Genentech, among others, are investing in start-ups and solutions for AI-based clinical trials to lower the costs of clinical trials. Consequently, it is anticipated that as the number of clinical trials in the field rises, so will the demand for solutions that may expedite the process and lessen its numerous difficulties.

Medical diagnosis is expected to be the fastest-growing segment. The high usage of AI-based solutions to create chatbots and mobile apps to diagnose several typical symptoms is the primary factor driving the immense growth of AI in medical diagnosis applications. Core applications needed for significant healthcare companies are also witnessing high demand in the global market. Solutions studying and identifying diseases from medical imaging and live patient symptoms are increasingly becoming popular in diagnosis applications, especially in regions with fewer medical professionals.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Regional Analysis

The global artificial intelligence (AI) in life sciences market share is segmented into four regions, namely North America, Europe, Asia-Pacific, and the Rest of the World.

North America is the most significant shareholder in the global artificial intelligence (AI) in life sciences market and is estimated to grow at a CAGR of 26.6% during the forecast period. The United States is the largest market because of the substantial demand for AI solutions from virtually all life science applications. The country has a huge demand for AI solutions for drug discovery, precision medicine, and biotechnology applications. According to the FDA's Drug Trail Snapshot Report-2019, more than 27% of patients participating in drug trials were of Asian or Hispanic ethnicity, while only 40% of all clinical trial participants were Americans. This scenario is anticipated to significantly increase demand for applications of personalized medicine using AI technology during the forecast period.

Asia-Pacific's Market Trends

Asia-Pacific is expected to grow at a CAGR of 30.2%, generating USD 3,775 million during the forecast period. China's biotechnology sector has experienced double-digit growth, moving from one of the nations with the slowest adoption rates to one of the fastest. Also, key players are focusing on establishing a drug research center in China that caters to market growth. The study published in the journal JAMA Cardiology showed that the Chinese population's annual deaths from cardiovascular disease increased from 2.51 million to 3.97 million in 2018. Thus it is anticipated that the demand for AI monitoring patients will support the artificial intelligence (AI) in life sciences market growth during the forecast period.

Europe's Market Trends

The fastest-growing region is Europe, with Germany representing the biggest regional market for AI in the life sciences. The country has some of the best research facilities in the world, providing a suitable environment for the growth of clinical trials. According to Lymphoma Coalition, Germany recorded the highest number of clinical trials in 2018, at 120, closely followed by Italy, which conducted 119 trials. The German government is involved in the field as it provides country-wide financial support for AI, such as proposed investments amounting to EUR 3 billion by 2025. It also aids in applying technological progress in social and healthcare improvement. According to the Office for Life Sciences, Germany is the second-largest European country with the most productive pharmaceutical manufacturing sectors. Such factors are expected to drive more investment into the country's drug discovery applications, creating considerable demand for AI solutions over the forecast period.

Unlock Regional Insightsto access country-level data, & regional trends.

List of Key and Emerging Players in Artificial Intelligence (AI) in Life Sciences Market